These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 38447451)

  • 1. Changes in chromatin accessibility and transcriptional landscape induced by HDAC inhibitors in TP53 mutated patient-derived colon cancer organoids.
    Gagliano T; Kerschbamer E; Baccarani U; Minisini M; Di Giorgio E; Dalla E; Weichenberger CX; Cherchi V; Terrosu G; Brancolini C
    Biomed Pharmacother; 2024 Apr; 173():116374. PubMed ID: 38447451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histone deacetylase inhibitors potentiate photodynamic therapy in colon cancer cells marked by chromatin-mediated epigenetic regulation of
    Halaburková A; Jendželovský R; Kovaľ J; Herceg Z; Fedoročko P; Ghantous A
    Clin Epigenetics; 2017; 9():62. PubMed ID: 28603560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pax5 Re-expression in H460 Cells Treated with the Combination of Demethylating Agent and Histone Deacetylase Inhibitor is Associated with the Enhancement of P53 Binding to Pax5 Promoter Region.
    Liang Y; Zeng J; Jelicks L; Ma S; Liu J; Mei J; Perez-Soler R; Zou Y
    Curr Cancer Drug Targets; 2017; 17(2):169-176. PubMed ID: 27029827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transcriptomic and genomic studies classify NKL54 as a histone deacetylase inhibitor with indirect influence on MEF2-dependent transcription.
    Minisini M; Di Giorgio E; Kerschbamer E; Dalla E; Faggiani M; Franforte E; Meyer-Almes FJ; Ragno R; Antonini L; Mai A; Fiorentino F; Rotili D; Chinellato M; Perin S; Cendron L; Weichenberger CX; Angelini A; Brancolini C
    Nucleic Acids Res; 2022 Mar; 50(5):2566-2586. PubMed ID: 35150567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The histone deacetylase inhibitor panobinostat exerts anticancer effects on esophageal squamous cell carcinoma cells by inducing cell cycle arrest.
    Cheng YW; Liao LD; Yang Q; Chen Y; Nie PJ; Zhang XJ; Xie JJ; Shan BE; Zhao LM; Xu LY; Li EM
    Cell Biochem Funct; 2018 Dec; 36(8):398-407. PubMed ID: 30484863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergy between histone deacetylase inhibitors and DNA-damaging agents is mediated by histone deacetylase 2 in colorectal cancer.
    Alzoubi S; Brody L; Rahman S; Mahul-Mellier AL; Mercado N; Ito K; El-Bahrawy M; Silver A; Boobis A; Bell JD; Hajji N
    Oncotarget; 2016 Jul; 7(28):44505-44521. PubMed ID: 27283986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suberoylanilide hydroxamic acid increases anti-cancer effect of tumor necrosis factor-α through up-regulation of TNF receptor 1 in lung cancer cells.
    You BR; Han BR; Park WH
    Oncotarget; 2017 Mar; 8(11):17726-17737. PubMed ID: 28099148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
    Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
    Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of a less aggressive phenotype in human colon carcinoma HCT116 cells by chronic exposure to HDAC inhibitor SAHA.
    Bressan A; Bigioni M; Bellarosa D; Nardelli F; Irrissuto C; Maggi CA; Binaschi M
    Oncol Rep; 2010 Nov; 24(5):1249-55. PubMed ID: 20878117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MLH1 protects from resistance acquisition by the histone deacetylase inhibitor trichostatin A in colon tumor cells.
    Imesch P; Dedes KJ; Furlato M; Fink D; Fedier A
    Int J Oncol; 2009 Sep; 35(3):631-40. PubMed ID: 19639184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells.
    Fedier A; Dedes KJ; Imesch P; Von Bueren AO; Fink D
    Int J Oncol; 2007 Sep; 31(3):633-41. PubMed ID: 17671692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of Radiosensitization by HDAC Inhibitors CUDC-101 and SAHA in Pancreatic Cancer Cells.
    Moertl S; Payer S; Kell R; Winkler K; Anastasov N; Atkinson MJ
    Int J Mol Sci; 2019 Jul; 20(13):. PubMed ID: 31269745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of histone deacetylase in cancer cells slows down replication forks, activates dormant origins, and induces DNA damage.
    Conti C; Leo E; Eichler GS; Sordet O; Martin MM; Fan A; Aladjem MI; Pommier Y
    Cancer Res; 2010 Jun; 70(11):4470-80. PubMed ID: 20460513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apoptosis signal-regulating kinase 1 is a direct target of E2F1 and contributes to histone deacetylase inhibitor-induced apoptosis through positive feedback regulation of E2F1 apoptotic activity.
    Tan J; Zhuang L; Jiang X; Yang KK; Karuturi KM; Yu Q
    J Biol Chem; 2006 Apr; 281(15):10508-15. PubMed ID: 16476732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel SAHA analogues inhibit HDACs, induce apoptosis and modulate the expression of microRNAs in hepatocellular carcinoma.
    Srinivas C; Swathi V; Priyanka C; Anjana Devi T; Subba Reddy BV; Janaki Ramaiah M; Bhadra U; Bhadra MP
    Apoptosis; 2016 Nov; 21(11):1249-1264. PubMed ID: 27502208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines.
    Sakajiri S; Kumagai T; Kawamata N; Saitoh T; Said JW; Koeffler HP
    Exp Hematol; 2005 Jan; 33(1):53-61. PubMed ID: 15661398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative effects of histone deacetylase inhibitors on p53 target gene expression, cell cycle and apoptosis in MCF-7 breast cancer cells.
    Knutson AK; Welsh J; Taylor T; Roy S; Wang WL; Tenniswood M
    Oncol Rep; 2012 Mar; 27(3):849-53. PubMed ID: 22159450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vorinostat-induced apoptosis in mantle cell lymphoma is mediated by acetylation of proapoptotic BH3-only gene promoters.
    Xargay-Torrent S; López-Guerra M; Saborit-Villarroya I; Rosich L; Campo E; Roué G; Colomer D
    Clin Cancer Res; 2011 Jun; 17(12):3956-68. PubMed ID: 21652541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Histone-Deacetylase-Inhibitor Suberoylanilide Hydroxamic Acid Promotes Dental Pulp Repair Mechanisms Through Modulation of Matrix Metalloproteinase-13 Activity.
    Duncan HF; Smith AJ; Fleming GJ; Partridge NC; Shimizu E; Moran GP; Cooper PR
    J Cell Physiol; 2016 Apr; 231(4):798-816. PubMed ID: 26264761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy.
    Chen MY; Liao WS; Lu Z; Bornmann WG; Hennessey V; Washington MN; Rosner GL; Yu Y; Ahmed AA; Bast RC
    Cancer; 2011 Oct; 117(19):4424-38. PubMed ID: 21491416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.